Clinical trial
Combination Therapy of Severe Aplastic Anemia
NCT00001964 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00001964 |
|---|---|
| Title | Combination Therapy of Severe Aplastic Anemia |
| Official title | Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF) |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Severe Aplastic Anemia |
| Intervention type | Drug |
| Interventions | Cyclosporine A, ATG, MMF |
| Enrollment | 104 |
| Start date | Mar 17, 2000 |
| Primary completion | Dec 9, 2003 |
| Completion | May 12, 2015 |
| First posted | Jan 19, 2000 |
| Last update posted | Mar 16, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: